CALCA and migraine disorder: In a second retrospective chart review of concussed patients with a PTH migraine phenotype, a preliminary analysis found that 3 anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab) reduced headache severity and frequency while also decreasing the number of concussion symptoms (42).